Genetic Determinants Of Inherited Optic Neuropathies
Funder
National Health and Medical Research Council
Funding Amount
$249,750.00
Summary
Glaucoma is a slowly progressive visual disorder of the optic nerves often but not always associated with elevated pressure in the eyes. There is a strong genetic component. It is estimated to affect in excess of 60 million people worldwide with more than 6 million of those blind in both eyes. It is the second commonest cause of visual impairment in the developed world, and is present in up to 10% of the population by age 90. Numbers of affected patients in Australia are expected to double in th ....Glaucoma is a slowly progressive visual disorder of the optic nerves often but not always associated with elevated pressure in the eyes. There is a strong genetic component. It is estimated to affect in excess of 60 million people worldwide with more than 6 million of those blind in both eyes. It is the second commonest cause of visual impairment in the developed world, and is present in up to 10% of the population by age 90. Numbers of affected patients in Australia are expected to double in the next 30 years. Current methods of early detection and treatment are often inadequate, and associated visual loss is irreversible. There is a strong need for greater understanding of the disease process and new strategies to prevent and treat visual loss. Two less common causes of untreatable optic nerve blindness are Leber Hereditary Optic Neuropathy (LHON) and autosomal dominant optic atrophy (ADOA) which occur in younger age groups than most cases of glaucoma, and hence sufferers may experience substantial physical, emotional and economic hardship. Over a 10 year period we have seen large numbers of patients with all three eye conditions and have developed a powerful study to determine the genes which cause optic nerve blindness and their relative importance. The research is gathering momentum and the genetics of all 3 conditions are now partly understood. This project seeks to analyse a new major glaucoma gene (Optineurin) in our Australian population and to try to understand the way in which a number of genes interact to cause blindness in some patients but not others. This work will lead to greater understanding of these causes of blindness and is likely to lead to new screening tests to know who is at most risk, and the opportunity to develop and test new treatments targeted to the underlying genetic problem.Read moreRead less
OXPHOS Upregulation To Preserve Vision In Leber's Hereditary Optic Neuropathy
Funder
National Health and Medical Research Council
Funding Amount
$496,874.00
Summary
Leber's Hereditary Optic Neuropathy (LHON) is a devastating blinding disease that preferentially affects young men. Sufferers have normal vision until teenage years or their twenties when a rapid loss of vision occurs that results in permanent blindness. It is caused by genetic changes in the mitochondrial DNA that we inherit from our mothers. The mitochondria are the cells' energy generators. We aim to use molecules similar to female hormones to boost energy as a new treatment to preserve visio ....Leber's Hereditary Optic Neuropathy (LHON) is a devastating blinding disease that preferentially affects young men. Sufferers have normal vision until teenage years or their twenties when a rapid loss of vision occurs that results in permanent blindness. It is caused by genetic changes in the mitochondrial DNA that we inherit from our mothers. The mitochondria are the cells' energy generators. We aim to use molecules similar to female hormones to boost energy as a new treatment to preserve vision in at-risk LHON individuals.Read moreRead less
Oxidative Phosphorylation Regulation And Neuroprotection In Optic Neuropathies
Funder
National Health and Medical Research Council
Funding Amount
$430,231.00
Summary
We have shown clear differences in the mitochodria, cellular organelles that generate energy, between optic atrophy patients who have good vision and those of patients who have poor vision. We believe that these changes represent a compensation mechanisms that preserves mitochondrial energy production and protects optic nerve cells. This study will characterize these differences further with the aim of identfying new treatments for preventing nerve loss and preserving vision.
Modelling Leber’s Hereditary Optic Neuropathy Using Human Induced Pluripotent Stem Cells
Funder
National Health and Medical Research Council
Funding Amount
$628,416.00
Summary
Leber’s Hereditary Optic Neuropathy (LHON) is a blinding disease that affects young males and is caused by the death of cells in the optic nerve. To better understand LHON, this project utilises induced pluripotent stem (iPS) cells for disease modelling. iPS cells will be generated from patients and turned into optic nerve cells, allowing us to study the diseased cells in the laboratory, providing a platform to screen for novel drugs to improve treatment options and fast-track drug development.
OCULAR PERFUSION PRESSURE: A MODIFIABLE RISK FACTOR FOR GLAUCOMA?
Funder
National Health and Medical Research Council
Funding Amount
$327,560.00
Summary
This project aims to study the mechanisms underlying glaucoma, the second leading cause of vision loss. Specifically it will provide proof for the idea that a person can develop vision loss without having high eye pressure, if their blood pressure cannot provide enough supply to the eye. It will achieve this by combining expertise from several disciplines; physiology, blood pressure control, anatomy and biochemistry. This project will help to improve glaucoma detection, monitoring and treatment.
Cutting Through Complexity: The Promise Of Biomarkers To Discover, Diagnose, And Treat Antibody-associated Demyelination
Funder
National Health and Medical Research Council
Funding Amount
$438,768.00
Summary
Patients with damage to myelin, the sheath around nerve cells in the brain, have “demyelinating disorders” which can result in severe disability including blindness and paralysis. In some patients, their immune system mistakenly targets certain proteins in the brain. This research project will identify new targets in currently undiagnosed patients, increase our understanding of underlying disease processes, and evaluate optimal treatment strategies in these patients to improve their outcomes.
We have discovered a single tumour factor which causes cancer cachexia, a wasting condition that is one of the worst complications of malignancy, for which there is no current effective treatment. We have developed antibodies which effectively block this condition in preclinical models and have produced human/humanised version of this. This application is to characterise these human antibodies to allow us proceed to clinical trials.
Can Exercise Early After Spinal Cord Injury Prevent Deterioration Of Muscle And Bone?
Funder
National Health and Medical Research Council
Funding Amount
$775,049.00
Summary
Spinal cord injury leads to a profound deterioration of the muscles and bones in the paralysed limbs. This project will examine the effects of exercising the paralysed limbs as early as possible after injury to prevent muscle and bone loss rather than restoring the tissues once changes have occurred. The time course and mechanisms underlying the microstructural decay of bone over the first year after injury will also be examined to provide a basis for determining fracture risk in this group.
Optic Nerve Head Structure And Genetic/environmental Associations: A Population-based SD-OCT Study
Funder
National Health and Medical Research Council
Funding Amount
$320,891.00
Summary
My research project combines two powerful new technologies, spectral domain-optical coherence tomography and the genome-wide association study, to investigate the physical and genetic characteristics of the optic nerve head in humans. Results from this work will help identify new glaucoma risk genes, increasing sensitivity and specificity for predicting glaucoma and expand our understanding of the disease mechanism allowing for the development of new treatments.